Ian Paterson Newton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ian Paterson Newton has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Inke Näthke
School of Life Sciences, University of Dundee, Dundee, United Kingdom
29 shared publications - Joao A. Paulo
Department of Cell Biology, Harvard Medical School, Boston, MA, USA
20 shared publications - Kevin M. Haigis
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA
20 shared publications Alejandro Rojas-Fernandez
19 shared publicationsJens Januschke
19 shared publications- Melanie S. Volk
Cell and Developmental Biology, School of Life Sciences, University of Dundee, Dundee, Scotland, United Kingdom
19 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in European Journal of Immunology
- Vol. 56 (10)
Parasite‐Derived IL‐33 Inhibitors Prevent Bleomycin‐Induced Lung Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive lung‐scarring disease in which epithelial injury, consequent release of alarmins such as interleukin (IL)‐33, and immune activation contribute to extracellular matrix deposition. The intestinal helminth Heligmosomoides polygyrus bakeri ( Hpb ) secretes immunomodulators that suppress type 2 immunity, including HpARI2, which binds IL‐33, and HpBARI_Hom2, which blocks the IL‐33 receptor ST2. Here, we test this parasite‐derived dual blockade strategy in the bleomycin (BLM) mouse model, moving from live Hpb infection to administration of total Hpb excretory/secretory products (HES), and finally administering recombinant HpARI2 and HpBARI_Hom2 proteins. Hpb infection and HES treatment prevented BLM‐induced lung fibrosis when administered during the early inflammatory phase. Recombinant HpARI2+HpBARI_Hom2 reproduced this protection, reduced collagen deposition and hydroxyproline accumulation, and dampened ILC2, eosinophil, macrophage, and neutrophil responses. In contrast, HES or HpARI2+HpBARI_Hom2 administration failed to reverse established fibrosis when administered later in the model. Similarly, administration of the IL‐33trap fusion protein could replicate these effects, suppressing fibrosis when administered in the early inflammatory, but not later fibrotic phases of this model. These findings identify parasite‐derived inhibition of the IL‐33 axis as a defined molecular mechanism by which helminth products can prevent early inflammatory fibrogenesis, while also demonstrating that IL‐33 blockade is unlikely to reverse established lung scarring.
- 8 October 2026
- Published by Wiley in European Journal of Immunology
- Vol. 56 (10)
Open AccessParasite‐Derived IL‐33 Inhibitors Prevent Bleomycin‐Induced Lung Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive lung‐scarring disease in which epithelial injury, consequent release of alarmins such as interleukin (IL)‐33, and immune activation contribute to extracellular matrix deposition. The intestinal helminth Heligmosomoides polygyrus bakeri ( Hpb ) secretes immunomodulators that suppress type 2 immunity, including HpARI2, which binds IL‐33, and HpBARI_Hom2, which blocks the IL‐33 receptor ST2. Here, we test this parasite‐derived dual blockade strategy in the bleomycin (BLM) mouse model, moving from live Hpb infection to administration of total Hpb excretory/secretory products (HES), and finally administering recombinant HpARI2 and HpBARI_Hom2 proteins. Hpb infection and HES treatment prevented BLM‐induced lung fibrosis when administered during the early inflammatory phase. Recombinant HpARI2+HpBARI_Hom2 reproduced this protection, reduced collagen deposition and hydroxyproline accumulation, and dampened ILC2, eosinophil, macrophage, and neutrophil responses. In contrast, HES or HpARI2+HpBARI_Hom2 administration failed to reverse established fibrosis when administered later in the model. Similarly, administration of the IL‐33trap fusion protein could replicate these effects, suppressing fibrosis when administered in the early inflammatory, but not later fibrotic phases of this model. These findings identify parasite‐derived inhibition of the IL‐33 axis as a defined molecular mechanism by which helminth products can prevent early inflammatory fibrogenesis, while also demonstrating that IL‐33 blockade is unlikely to reverse established lung scarring.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Adenomatous Polyposis Coli (APC) is the most frequently mutated gene in colorectal cancer. APC negatively regulates the Wnt signaling pathway by promoting the degradation of β-catenin, but the extent to which APC exerts Wnt/β-catenin–independent tumor-suppressive activity is unclear. To identify interaction partners and β-catenin–independent targets of endogenous, full-length APC, we applied label-free and multiplexed tandem mass tag-based mass spectrometry. Affinity enrichment-mass spectrometry identified more than 150 previously unidentified APC interaction partners. Moreover, our global proteomic analysis revealed that roughly half of the protein expression changes that occur in response to APC loss are independent of β-catenin. Combining these two analyses, we identified Misshapen-like kinase 1 (MINK1) as a putative substrate of an APC-containing destruction complex. We validated the interaction between endogenous MINK1 and APC and further confirmed the negative, and β-catenin–independent, regulation of MINK1 by APC. Increased Mink1/Msn levels were also observed in mouse intestinal tissue and Drosophila follicular cells expressing mutant Apc/APC when compared with wild-type tissue/cells. Collectively, our results highlight the extent and importance of Wnt-independent APC functions in epithelial biology and disease.Implications:The tumor-suppressive function of APC, the most frequently mutated gene in colorectal cancer, is mainly attributed to its role in β-catenin/Wnt signaling. Our study substantially expands the list of APC interaction partners and reveals that approximately half of the changes in the cellular proteome induced by loss of APC function are mediated by β-catenin–independent mechanisms.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Adenomatous Polyposis Coli (APC) is the most frequently mutated gene in colorectal cancer. APC negatively regulates the Wnt signaling pathway by promoting the degradation of β-catenin, but the extent to which APC exerts Wnt/β-catenin–independent tumor-suppressive activity is unclear. To identify interaction partners and β-catenin–independent targets of endogenous, full-length APC, we applied label-free and multiplexed tandem mass tag-based mass spectrometry. Affinity enrichment-mass spectrometry identified more than 150 previously unidentified APC interaction partners. Moreover, our global proteomic analysis revealed that roughly half of the protein expression changes that occur in response to APC loss are independent of β-catenin. Combining these two analyses, we identified Misshapen-like kinase 1 (MINK1) as a putative substrate of an APC-containing destruction complex. We validated the interaction between endogenous MINK1 and APC and further confirmed the negative, and β-catenin–independent, regulation of MINK1 by APC. Increased Mink1/Msn levels were also observed in mouse intestinal tissue and Drosophila follicular cells expressing mutant Apc/APC when compared with wild-type tissue/cells. Collectively, our results highlight the extent and importance of Wnt-independent APC functions in epithelial biology and disease.Implications:The tumor-suppressive function of APC, the most frequently mutated gene in colorectal cancer, is mainly attributed to its role in β-catenin/Wnt signaling. Our study substantially expands the list of APC interaction partners and reveals that approximately half of the changes in the cellular proteome induced by loss of APC function are mediated by β-catenin–independent mechanisms.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Adenomatous Polyposis Coli (APC) is the most frequently mutated gene in colorectal cancer. APC negatively regulates the Wnt signaling pathway by promoting the degradation of β-catenin, but the extent to which APC exerts Wnt/β-catenin–independent tumor-suppressive activity is unclear. To identify interaction partners and β-catenin–independent targets of endogenous, full-length APC, we applied label-free and multiplexed tandem mass tag-based mass spectrometry. Affinity enrichment-mass spectrometry identified more than 150 previously unidentified APC interaction partners. Moreover, our global proteomic analysis revealed that roughly half of the protein expression changes that occur in response to APC loss are independent of β-catenin. Combining these two analyses, we identified Misshapen-like kinase 1 (MINK1) as a putative substrate of an APC-containing destruction complex. We validated the interaction between endogenous MINK1 and APC and further confirmed the negative, and β-catenin–independent, regulation of MINK1 by APC. Increased Mink1/Msn levels were also observed in mouse intestinal tissue and Drosophila follicular cells expressing mutant Apc/APC when compared with wild-type tissue/cells. Collectively, our results highlight the extent and importance of Wnt-independent APC functions in epithelial biology and disease.Implications:The tumor-suppressive function of APC, the most frequently mutated gene in colorectal cancer, is mainly attributed to its role in β-catenin/Wnt signaling. Our study substantially expands the list of APC interaction partners and reveals that approximately half of the changes in the cellular proteome induced by loss of APC function are mediated by β-catenin–independent mechanisms.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Adenomatous Polyposis Coli (APC) is the most frequently mutated gene in colorectal cancer. APC negatively regulates the Wnt signaling pathway by promoting the degradation of β-catenin, but the extent to which APC exerts Wnt/β-catenin–independent tumor-suppressive activity is unclear. To identify interaction partners and β-catenin–independent targets of endogenous, full-length APC, we applied label-free and multiplexed tandem mass tag-based mass spectrometry. Affinity enrichment-mass spectrometry identified more than 150 previously unidentified APC interaction partners. Moreover, our global proteomic analysis revealed that roughly half of the protein expression changes that occur in response to APC loss are independent of β-catenin. Combining these two analyses, we identified Misshapen-like kinase 1 (MINK1) as a putative substrate of an APC-containing destruction complex. We validated the interaction between endogenous MINK1 and APC and further confirmed the negative, and β-catenin–independent, regulation of MINK1 by APC. Increased Mink1/Msn levels were also observed in mouse intestinal tissue and Drosophila follicular cells expressing mutant Apc/APC when compared with wild-type tissue/cells. Collectively, our results highlight the extent and importance of Wnt-independent APC functions in epithelial biology and disease.Implications:The tumor-suppressive function of APC, the most frequently mutated gene in colorectal cancer, is mainly attributed to its role in β-catenin/Wnt signaling. Our study substantially expands the list of APC interaction partners and reveals that approximately half of the changes in the cellular proteome induced by loss of APC function are mediated by β-catenin–independent mechanisms.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Control APC interactome network
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Control APC interactome network
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
APC Affinity enrichment-mass spectrometry (AE-MS)
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
APC Affinity enrichment-mass spectrometry (AE-MS)
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
MINK1 binds to and is negatively regulated by APC
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
MINK1 binds to and is negatively regulated by APC
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Beta-catenin-independent and -dependent APC targets identified by TMT label and label-free mass spectrometry
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Beta-catenin-independent and -dependent APC targets identified by TMT label and label-free mass spectrometry
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Changes in protein abundances in response to APC depletion
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Changes in protein abundances in response to APC depletion
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Validation of APC interactors identified by AE-MS
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
Validation of APC interactors identified by AE-MS
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S1 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
APC Affinity enrichment-mass spectrometry (AE-MS)
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Identification of Endogenous Adenomatous Polyposis Coli Interaction Partners and β-Catenin–Independent Targets by Proteomics
APC Affinity enrichment-mass spectrometry (AE-MS)